VIDEO: CancerX offers ‘unparalleled opportunity’ to collaborate with health care leaders
Key takeaways:
- Lind’s AI-based platform is designed to help people with cancer quickly match to appropriate clinical trials.
- The company participated in the inaugural CancerX Accelerator cohort.
A precision trial matching platform is designed to help people with cancer quickly identify and access appropriate treatment options.
The AI-based platform — developed by Lind — allows patients to upload documents or connect to their electronic health record. Patients are matched with clinical trials based on their preferences and medical history, and they receive a personalized report intended to support their consideration for clinical trial enrollment.
“In the last year, we successfully developed and validated our clinical trial screening platform,” Oggie Nikolic, founder and CEO of Lind, told Healio. “We have substantiated its performance through co-publications with leading health systems and National Cancer Institute collaborations, and we have developed a go-to market and health care system deployment playbook to get to as many patients and as many clinicians as possible.”
Lind participated in the inaugural cohort of the CancerX Accelerator, hosted by Moffitt Cancer Center and launched in collaboration with the Office of the National Coordinator for Health Information Technology and the Office of the Assistant Secretary for Health.
The 16 startups in the cohort collaborated with accelerator champions, mentors, federal partners and CancerX members throughout the health care system to test and validate innovative solutions intended to improve the lives of people with cancer.
“CancerX represents a unique and unparallelled opportunity to collaborate with a diverse ecosystem of health care leaders that span health systems, sponsors, government agencies, payors, patients [and] patient advocates,” Nikolic said. “This was formative for our company.”
In this video, Nikolic shares insights into why he wanted to participate in the CancerX Accelerator, how this experience benefitted him and the company, and his advice to members of the 2025 CancerX Accelerator cohort.
Healio has been selected as the official media partner of the 2025 CancerX Accelerator cohort.
Join the CancerX community here.
References:
- Lind. https://www.lind.care. Accessed March 18, 2025.
- CancerX. https://cancerx.health. Accessed March 17, 2025.
For more information:
Oggie Nikolic can be reached on LinkedIn here.